StockNews.com Begins Coverage on Aspira Women’s Health (NASDAQ:AWH)

StockNews.com initiated coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a report issued on Wednesday. The firm issued a hold rating on the stock.

Separately, Alliance Global Partners cut their target price on Aspira Women’s Health from $7.00 to $5.50 and set a buy rating for the company in a research note on Wednesday, August 14th.

Aspira Women’s Health Stock Performance

NASDAQ AWH opened at $0.83 on Wednesday. Aspira Women’s Health has a one year low of $0.74 and a one year high of $6.01. The firm has a market cap of $13.28 million, a PE ratio of -0.57 and a beta of 1.47. The firm’s fifty day moving average is $1.01 and its two-hundred day moving average is $1.94.

Aspira Women’s Health (NASDAQ:AWH) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. The firm had revenue of $2.42 million during the quarter, compared to analysts’ expectations of $2.60 million. During the same quarter last year, the business earned ($0.28) earnings per share. Research analysts predict that Aspira Women’s Health will post -1.26 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. grew its position in Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 236,396 shares of the company’s stock after buying an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent quarter. 12.19% of the stock is owned by institutional investors and hedge funds.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.